Research programme: bispecific monoclonal antibody therapeutics - J Ints Bio
Latest Information Update: 28 Jun 2024
At a glance
- Originator Joseah Biopharma
- Developer J Ints Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 29 May 2020 Preclinical trials in Cancer in South Korea (Parenteral), before May 2020 (Joseah Biopharma Pipeline, May 2020)